Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 905, doi. 10.1007/s40264-023-01336-x
- By:
- Publication type:
- Article
Works matching IS 01145916 AND DT 2023 AND VI 46 AND IP 9
Results: 10
1
2
The QT<sub>c-Bazett</sub> Interval in Former Very Preterm Infants in Adolescence and Young Adulthood is Not Different from Term-Born Controls.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 897, doi. 10.1007/s40264-023-01335-y
- By:
- Publication type:
- Article
3
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 881, doi. 10.1007/s40264-023-01334-z
- By:
- Publication type:
- Article
4
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 867, doi. 10.1007/s40264-023-01332-1
- By:
- Publication type:
- Article
5
Authors' Reply to Cappello et al. Comment on: "Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System".
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 919, doi. 10.1007/s40264-023-01331-2
- By:
- Publication type:
- Article
6
Comment on: "Deliberate Self-Poisoning: Real-Time Characterisation of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System".
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
7
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 857, doi. 10.1007/s40264-023-01329-w
- By:
- Publication type:
- Article
8
Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical Utility.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 847, doi. 10.1007/s40264-023-01327-y
- By:
- Publication type:
- Article
9
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 835, doi. 10.1007/s40264-023-01326-z
- By:
- Publication type:
- Article
10
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
- Published in:
- Drug Safety, 2023, v. 46, n. 9, p. 819, doi. 10.1007/s40264-023-01320-5
- By:
- Publication type:
- Article